Published in J Antibiot (Tokyo) on April 01, 2006
Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev (2009) 5.76
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2011) 1.26
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother (2008) 1.21
Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol (2012) 1.17
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother (2009) 1.02
The role of carbapenems in initial therapy for serious Gram-negative infections. Crit Care (2008) 1.00
Deciphering the function of the outer membrane protein OprD homologue of Acinetobacter baumannii. Antimicrob Agents Chemother (2012) 0.93
Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother (2013) 0.92
Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother (2008) 0.91
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob Agents Chemother (2007) 0.90
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob Agents Chemother (2008) 0.88
Emergence of carbapenem resistance due to the novel insertion sequence ISPa8 in Pseudomonas aeruginosa. PLoS One (2014) 0.87
Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates. Eur J Clin Microbiol Infect Dis (2010) 0.80
Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent) (2008) 0.80
Evaluation of phenotypic detection methods for metallo-β-lactamases (MBLs) in clinical isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis (2014) 0.78
Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis. Eur J Clin Microbiol Infect Dis (2008) 0.77
Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use. Crit Care (2008) 0.75
Investigation of OprD Porin Protein Levels in Carbapenem-Resistant Pseudomonas aeruginosa Isolates. Jundishapur J Microbiol (2015) 0.75
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother (2007) 2.23
Novel plasmid-mediated 16S rRNA methylase, RmtC, found in a proteus mirabilis isolate demonstrating extraordinary high-level resistance against various aminoglycosides. Antimicrob Agents Chemother (2006) 1.98
Where has vancomycin-heterogeneously resistant Staphylococcus aureus gone? Lancet (2004) 1.55
Possible connection between a widely disseminated conjugative gentamicin resistance (pMG1-like) plasmid and the emergence of vancomycin resistance in Enterococcus faecium. J Clin Microbiol (2002) 1.51
Mode of transposition and expression of 16S rRNA methyltransferase gene rmtC accompanied by ISEcp1. Antimicrob Agents Chemother (2006) 1.42
Horizontal transfer of blaCMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19. Antimicrob Agents Chemother (2006) 1.22
Genetic analysis of transfer-related regions of the vancomycin resistance Enterococcus conjugative plasmid pHTbeta: identification of oriT and a putative relaxase gene. J Bacteriol (2005) 1.01
Molecular characterization of vancomycin-resistant enterococcus faecium isolates from mainland China. J Clin Microbiol (2007) 0.99
Highly conjugative pMG1-like plasmids carrying Tn1546-like transposons that encode vancomycin resistance in Enterococcus faecium. J Bacteriol (2003) 0.98
Analysis of the conjugal transfer system of the pheromone-independent highly transferable Enterococcus plasmid pMG1: identification of a tra gene (traA) up-regulated during conjugation. J Bacteriol (2002) 0.96
Isolation of VanB-type Enterococcus faecalis strains from nosocomial infections: first report of the isolation and identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-type vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, encoding erythromycin resistance and cytolysin (Hly/Bac). Antimicrob Agents Chemother (2008) 0.96
Tissue-specific adherent Enterococcus faecalis strains that show highly efficient adhesion to human bladder carcinoma T24 cells also adhere to extracellular matrix proteins. Infect Immun (2004) 0.94
Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-beta. Lab Invest (2004) 0.94
Vancomycin-resistant enterococci in humans and imported chickens in Japan. Appl Environ Microbiol (2002) 0.92
Replication of Enterococcus faecalis pheromone-responding plasmid pAD1: location of the minimal replicon and oriV site and RepA involvement in initiation of replication. J Bacteriol (2004) 0.91
Bac 32, a novel bacteriocin widely disseminated among clinical isolates of Enterococcus faecium. Antimicrob Agents Chemother (2006) 0.91
Phenotypic and genetic characterization of vancomycin-resistant enterococci from hospitalized humans and from poultry in Korea. FEMS Microbiol Lett (2006) 0.90
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob Agents Chemother (2008) 0.88
Pheromone-responsive conjugative vancomycin resistance plasmids in Enterococcus faecalis isolates from humans and chicken feces. Appl Environ Microbiol (2006) 0.88
A comparison of the movement characteristics between the kneeling gait and the normal gait in healthy adults. Gait Posture (2012) 0.86
Role of the CpxAR two-component signal transduction system in control of fosfomycin resistance and carbon substrate uptake. J Bacteriol (2013) 0.86
Assessment of antibiotic resistance in probiotic strain Lactobacillus brevis KB290. J Food Prot (2009) 0.86
Complete nucleotide sequencing and analysis of the 65-kb highly conjugative Enterococcus faecium plasmid pMG1: identification of the transfer-related region and the minimum region required for replication. FEMS Microbiol Lett (2008) 0.86
Identification of VanN-type vancomycin resistance in an Enterococcus faecium isolate from chicken meat in Japan. Antimicrob Agents Chemother (2012) 0.85
Contribution of secreted proteases to the pathogenesis of postoperative Enterococcus faecalis endophthalmitis. J Cataract Refract Surg (2008) 0.83
Interference of bacterial cell-to-cell communication: a new concept of antimicrobial chemotherapy breaks antibiotic resistance. Front Microbiol (2013) 0.82
Genetic analysis of bacteriocin 43 of vancomycin-resistant Enterococcus faecium. Appl Environ Microbiol (2006) 0.82
Identification of novel genes responsible for overexpression of ampC in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother (2013) 0.81
Drug resistance of Enterococcus faecium clinical isolates and the conjugative transfer of gentamicin and erythromycin resistance traits. FEMS Microbiol Lett (2005) 0.81
Bacteriocin protein BacL1 of Enterococcus faecalis is a peptidoglycan D-isoglutamyl-L-lysine endopeptidase. J Biol Chem (2013) 0.80
First VanD-Type vancomycin-resistant Enterococcus raffinosus isolate. Antimicrob Agents Chemother (2006) 0.79
VanB-vanA incongruent VRE isolated from animals and humans in 1999. J Microbiol (2006) 0.79
Genetic organization and mode of action of a novel bacteriocin, bacteriocin 51: determinant of VanA-type vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother (2011) 0.79
Investigating a catalytic mechanism of hyperthermophilic L-threonine dehydrogenase from Pyrococcus horikoshii. J Biochem (2008) 0.79
Nationwide epidemiological study revealed the dissemination of meticillin-resistant Staphylococcus aureus carrying a specific set of virulence-associated genes in Japanese hospitals. J Med Microbiol (2009) 0.78
Nosocomial infection caused by vancomycin-susceptible multidrug-resistant Enterococcus faecalis over a long period in a university hospital in Japan. Microbiol Immunol (2014) 0.77
Pandemic influenza virus surveillance, Izu-Oshima Island, Japan. Emerg Infect Dis (2012) 0.76
Corrigendum: Plasmodium berghei ANKA causes intestinal malaria associated with dysbiosis. Sci Rep (2016) 0.75
Alteration of metal ions improves the activity and thermostability of aminoacylase from hyperthermophilic archaeon Pyrococcus horikoshii. Biotechnol Lett (2008) 0.75
[Vancomycin (VCM) resistant enterococci (VRE)]. Nihon Rinsho (2003) 0.75
[New class of Acyl-homoserine lactone quorum sensing signals]. Nihon Saikingaku Zasshi (2013) 0.75
Award Lecture. Nihon Saikingaku Zasshi (2016) 0.75
[Positioning of various anti-bacterial agents and their appropriate use in the era of multiple bacterial drug resistance. 8. Glycopeptides]. Nihon Naika Gakkai Zasshi (2003) 0.75